Paradoxically, the N375S mutant exhibits decreased binding to HGF, instead conferring enhanced ligand-independent binding affinity to HER2 [95]; cancers with this mutation are insensitive to MET TKI treatment but may respond well to HER2-targeted therapy. This evidence concerns the gene ERBB2 and cancer.